Rapid antibiotic susceptibility test: Commercialization of life saving MEMS devices

摘要

For the timely treatment of patients with infections in bloodstream and cerebrospinal fluid, a rapid antimicrobial susceptibility test (AST) is urgently needed. This paper describe a direct and rapid antimicrobial susceptibility testing (dRAST) system, which can determine the antimicrobial susceptibility of bacteria from a positive blood culture bottle (PBCB) in six hours that conventionally taking more than 30-50 hours. Design consideration, clinical verification, commercialization, and application of dRAST system to tuberculosis are reviewed.